TRIM21 and neoplasm: In control cells, Sorafenib treatment markedly inhibited cell proliferation in vitro and suppressed tumor growth in vivo, whereas these effects were significantly blunted in TRIM21‐knockdown cells (Figure 6O‐P; Figure S4C,D, Supporting Information).